Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
ChinaBio® Investor Forum in Beijing Selects Two “Most Promising” Companies
publication date: Sep 7, 2012
|
author/source: Richard Daverman, PhD
The thirteenth ChinaBio® Investor Forum selected two early stage life science companies as the “Most Promising” of the 18 presenting companies: Optomed Oy from Finland and ASLAN Pharmaceuticals from Singapore. The ChinaBio event, which was held September 4-6, brought together more than 160 attendees from Finland, China, the US, Canada, Singapore, and Switzerland.
Optomed Oy (Ltd.) is a medical device company specializing in digital imaging devices that are smaller and more cost effective than competing devices, making them a good fit for the China market. The Optomed Smartscope® is a digital medical camera that provides opthalmoscopic, otoscopic and dermatoscopic imaging in a handheld format. This allows the device to be used in remote consultation and improves accurate first diagnosis as well as consistent follow-up. Based in Oulu, Finland, Optomed also has sales offices in Shanghai, China and the Philippines.
ASLAN Pharmaceuticals is a Singapore-based pharmaceutical company that develops novel medicines for the global market. ASLAN has in-licensed preclinical and clinical compounds from global pharma companies, focusing on oncology, respiratory and inflammatory diseases. ASLAN is leveraging resources across Asia, including China, Korea and Australia, as well as Singapore, to efficiently move its drug candidates through clinical development, with plans to partner with pharmaceutical companies for late phase global development and commercialization.
Supported by China-Finland Golden Bridge and the Beijing Daxing Bio-medicine Industry Park, the ChinaBio® Investor Forum 2012 – Beijing featured a separate track for companies from Finland. Golden Bridge helped organize a delegation of eight life science companies to present to the over 30 VCs and other investors in attendance. There were another 10 companies from China, the US, Canada, Singapore and Switzerland, making this the most international ChinaBio Investor Forum to date.
ChinaBio LLC has helped raise over $500 million in government and VC funding for emerging life science companies through these events and its other activities.
ChinaBio will hold its next ChinaBio Investor Forum on December, 5-6, 2012, in Guangzhou. (See www.CBIF2012-GZ.com for more information.)
Optomed Oy (Ltd.) is a medical device company specializing in digital imaging devices that are smaller and more cost effective than competing devices, making them a good fit for the China market. The Optomed Smartscope® is a digital medical camera that provides opthalmoscopic, otoscopic and dermatoscopic imaging in a handheld format. This allows the device to be used in remote consultation and improves accurate first diagnosis as well as consistent follow-up. Based in Oulu, Finland, Optomed also has sales offices in Shanghai, China and the Philippines.
ASLAN Pharmaceuticals is a Singapore-based pharmaceutical company that develops novel medicines for the global market. ASLAN has in-licensed preclinical and clinical compounds from global pharma companies, focusing on oncology, respiratory and inflammatory diseases. ASLAN is leveraging resources across Asia, including China, Korea and Australia, as well as Singapore, to efficiently move its drug candidates through clinical development, with plans to partner with pharmaceutical companies for late phase global development and commercialization.
Supported by China-Finland Golden Bridge and the Beijing Daxing Bio-medicine Industry Park, the ChinaBio® Investor Forum 2012 – Beijing featured a separate track for companies from Finland. Golden Bridge helped organize a delegation of eight life science companies to present to the over 30 VCs and other investors in attendance. There were another 10 companies from China, the US, Canada, Singapore and Switzerland, making this the most international ChinaBio Investor Forum to date.
ChinaBio LLC has helped raise over $500 million in government and VC funding for emerging life science companies through these events and its other activities.
ChinaBio will hold its next ChinaBio Investor Forum on December, 5-6, 2012, in Guangzhou. (See www.CBIF2012-GZ.com for more information.)
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China
